ATOMWISE INC.

Products

Category

Product

Brand

Description

AI in Clinical and Molecular Diagnostics Market (BIO261A)

AtomNet		Atomwise's flagship technology, AtomNet, employs deep learning algorithms to forecast molecular interactions. This platform enables the rapid and precise screening of millions of compounds, effectively identifying promising candidates for drug development.
AI for Structure-Based Drug Design		The company uses AI to analyze and predict the interactions between small molecules and specific protein structures, facilitating the design of novel therapeutics.
Virtual Screening		Atomwise speeds up the initial stages of drug discovery by virtually screening extensive compound libraries to pinpoint molecules that can interact with biological targets.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment